Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Pretreated Patients

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3851-7 ◽

2016 ◽

Vol 158 (1) ◽

pp. 91-97 ◽

Cited By ~ 21

Author(s):

L. M. Smyth ◽

N. M. Iyengar ◽

M. F. Chen ◽

S. M. Popper ◽

S. Patil ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Progression Free Survival ◽

Weekly Paclitaxel ◽

Free Survival

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000722 ◽

2019 ◽

Vol 30 (4) ◽

pp. 394-401

Author(s):

Joachim Bischoff ◽

Jana Barinoff ◽

Christoph Mundhenke ◽

Dirk O. Bauerschlag ◽

Serban-Dan Costa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Pretreated Patients ◽

Her 2

Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study

10.1200/jco.2004.22.90140.783 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 783-783

Author(s):

T. Bouillet ◽

P. Saintigny ◽

E. Levy ◽

J.-P. Spano ◽

F. Morin ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Clinical Phase

Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result.

10.1200/jco.2015.33.15_suppl.607 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 607-607

Author(s):

Lillian Mary Smyth ◽

Neil M. Iyengar ◽

Sarat Chandarlapaty ◽

Steven Sugarman ◽

Elizabeth Anne Comen ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Progression Free Survival ◽

Weekly Paclitaxel ◽

Free Survival ◽

Survival Result

Phase II study of weekly paclitaxel for docetaxel-resistant or -inapplicable metastatic breast cancer: Preliminary results

European Journal of Cancer ◽

10.1016/s0959-8049(02)80221-0 ◽

2002 ◽

Vol 38 (11) ◽

pp. S73

Author(s):

T Ajhara

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Preliminary Results

Protein profiles (proteomics) discriminating between effect/no effect of weekly paclitaxel: A phase II study in metastatic breast cancer (BC)

10.1200/jco.2005.23.16_suppl.699 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 699-699

Author(s):

B. K. Linderholm ◽

J. Lehtio ◽

E. Lidbrink ◽

E. Ekman ◽

P. Karlsson ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Protein Profiles

Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).

10.1200/jco.2011.29.15_suppl.1119 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 1119-1119 ◽

Cited By ~ 2

Author(s):

Y. Ito ◽

K. Aogi ◽

N. Masuda ◽

S. Ohno ◽

T. Oda ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

First Line

Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer.

10.1158/0008-5472.sabcs12-p5-18-20 ◽

2012 ◽

Cited By ~ 4

Author(s):

F Datko ◽

G D'Andrea ◽

M Dickler ◽

M Theodoulou ◽

S Goldfarb ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel

Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer

Investigational New Drugs ◽

10.1007/s10637-012-9824-8 ◽

2012 ◽

Vol 31 (1) ◽

pp. 152-159 ◽

Cited By ~ 11

Author(s):

Keun Seok Lee ◽

In Hae Park ◽

Byung-Ho Nam ◽

Jungsil Ro

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pretreated Patients

PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.085 ◽

2017 ◽

Vol 28 ◽

pp. v107

Author(s):

D. Zardavas ◽

M. Regan ◽

R. Maibach ◽

B. Ruepp ◽

A. Hiltbrunner ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pretreated Patients